Prolong Pharmaceuticals
Manufacturing · New Jersey, United States · 51-200 Employees
View Company Info for Free
Overview
Headquarters
300 Corporate Ct Ste B, South Plainfield...Phone Number
(908) 444-4660Website
www.prolongpharma.comRevenue
$35.2 MillionIndustry
ZI Rank: 1
Signal Type
Dec
Jan
Feb
Mar
Apr
May
ZI Rank
2
2
1
1
1
1
About Prolong Pharmaceuticals
Prolong Pharmaceuticals is a clinical-stage biopharma leader focused on developing innovative treatments for complex diseases, particularly in the areas of CNS, Hematology, and Respiratory Disorders. Their products aim to address unmet medical needs such as Ischemia and Hypoxia within Stroke, Sickle Cell Disease, and Cystic Fibrosis. The company utilizes PEGylation technology to enhance drug delivery and efficacy, with their lead product, PP-007 (Sanguinate), designed to restore oxygen delivery to hypoxic tissues. Prolong Pharmaceuticals is committed to revolutionizing treatments for severe and life-threatening conditions through cutting-edge biopharma solutions.Explore more
Prolong Pharmaceuticals Org Chart
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is Prolong Pharmaceuticals your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Check out if Prolong Pharmaceuticals is spiking on competitors!
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Congratulate Masked Content for being promoted to Masked Content at Prolong Pharmaceuticals
Earning: See what the market has to say on Prolong Pharmaceuticals recently announced quarterly report
Check if Prolong Pharmaceuticals has recently received funding, and reach out quickly before it becomes old news!
Funding: Get notified immidiatlly once Prolong Pharmaceuticals has new funding data
Click to see if Prolong Pharmaceuticals had a recent Job posting/layoffs
Website visits: Recent activity has been detected on your website
Product Launch: Get notified when Prolong Pharmaceuticals launches new products
Prolong Pharmaceuticals, which may be a good buyer, showed buying intent in Masked Content Topic
Recommended Actions
Reach out to Masked Content who joined Prolong Pharmaceuticals as Masked Content
Find 2 more new buyers
Compare Similar Companies to Prolong Pharmaceuticals
Compare insights from companies similar to Prolong Pharmaceuticals, focusing on performance, financial data, growth rates, and unique benchmarks to identify key industry trends and opportunities.
Revenue
Number of Employees
Type
Funding
Founded In
Company Profile Activity
Activity Insights
Prolong Pharmaceuticals is experiencing very low activity levels compared to other companies in the Manufacturing sector.
What does this means?
Prolong Pharmaceuticals is drawing exceptional interest within the Manufacturing industry, suggesting notable developments or strong market momentum, learn more about Prolong Pharmaceuticals.
Prolong Pharmaceuticals financials insights
Gather financial insights about Prolong Pharmaceuticals, including details on funding rounds, investors, total funding, and acquisitions, to gain a comprehensive understanding of their financial strategy.
2020
Debt
$1M
Prolong Pharmaceuticals Tech Stack
A closer look at the technologies used by Prolong Pharmaceuticals
Prolong Pharmaceuticals News & Media
Prolong Pharmaceuticals to Present Clinical Data regarding PP-007, PEGylated carboxyhemoglobin bovine product, at the 2024 International Symposium on Blood Substitutes (ISBS)
SOUTH PLAINFIELD, N.J.--(BUSINESS WIRE)--Prolong Pharmaceuticals, LLC (the Company), a clinical-stage biopharmaceutical company, announced that the Company will deliver two oral presentations, an oral abstract, and two posters at the International Symposium on Blood Substitutes (ISBS) held on November 14-18, 2024, in National Harbor, Maryland. Oral Presentations Presenter: Dr. Shaunak Pandya, Director, CMC R&D, Prolong Pharmaceuticals Session: Updates on Bio-Synthetic Blood Components TitleU.S. Food and Drug Administration (FDA) Grants Prolong Pharmaceuticals FDA Fast Track Designation for Novel Stroke Therapy (PP-007) in HEMERA-1 Clinical Study
SOUTH PLAINFIELD, N.J.--(BUSINESS WIRE)--Prolong Pharmaceuticals, LLC, a clinical-stage biopharmaceutical company, announced today that its investigational therapy, PP-007 (PEGylated carboxyhemoglobin, bovine), has received Fast Track designation from the U.S. Food and Drug Administration (FDA) for the treatment of acute ischemic stroke (AIS). PP-007 is currently being evaluated for safety and efficacy in an ongoing U.S.-based clinical trial, HEMERA-1. "Receiving Fast Track designation underscoProlong Pharmaceuticals Announces Presentation of Phase 1 Data from HEMERA-1 Clinical Study of PP-007 in Patients with Acute Ischemic Stroke at the Late-Breaking Science Session, ISC 2023
SOUTH PLAINFIELD, N.J.--(BUSINESS WIRE)--Prolong Pharmaceuticals, a clinical stage biopharmaceutical company, today announced that preliminary data from the recently completed Phase 1 clinical study of PP-007 (HEMERA-1) in acute ischemic stroke (AIS) patients will be presented in the Late-Breaking Science session during ISC 2023 in Dallas, TX and in the forthcoming PAIRS conference in Dubai. PP-007 (PEGylated carboxyhemoglobin, bovine) is a novel investigational biopharmaceutical product that iProlong Pharmaceuticals to Present at the 36th Annual J.P. Morgan Healthcare Conference
SOUTH PLAINFIELD, N.J., Jan. 9, 2018 /PRNewswire/ -- Prolong Pharmaceuticals, a clinical stage biopharmaceutical company focusing on developing products to treat several diseases and their debilitating comorbidities associated with reduced quality of life, increased medical...
Read more news
Top Manufacturing Companies
Top companies in Australia by revenue
Top companies in New Zealand by revenue
Frequently Asked Questions Regarding Prolong Pharmaceuticals
Sign Up For FreeTo access detailed company insights
Prolong Pharmaceuticals is a clinical-stage biopharma leader focused on developing innovative treatments for complex diseases, particularly in the areas of CNS, Hematology, and Respiratory Disorders. Their products aim to address unmet medical needs such as Ischemia and Hypoxia within Stroke, Sickle Cell Disease, and Cystic Fibrosis. The company ut... Read More
